RxDoctor Payments Data

Paige McNash, APRN

Nurse Practitioner · Tampa, FLNPI 1083323752

Payments from drug & device makers

$10,036in general payments, 2019–2025

Across 390 payments — averaging $25.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$749
  • Lilly USA, LLC$593
  • Pfizer$533
  • Sanofi$515
  • plus $4K from 25 others

What the payments were for

  • Consulting fees$1,35013%
  • Food & beverage$8,61986%
  • Education$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,036 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$50,131
Medicare patients
267
Services billed
482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase18$119,970
LinzessLinaclotide30$35,118
IbsrelaTenapanor Hcl11$33,538
TrulancePlecanatide17$21,322
Colestipol Hcl64$4,744
Mesalamine29$4,685
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C23$3,318
Esomeprazole Magnesium28$3,147
Pantoprazole Sodium292$3,002
Famotidine159$2,538
Dicyclomine Hcl103$2,484
Omeprazole90$1,509
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates20$1,215
Sucralfate64$579
Lactulose28$274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,295$155,08848 claims
Ardelyx, Inc.Ibsrela$200$33,53811 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu$749$24,64040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →